Exosomes Derived hsa-miR-4669 as a Novel Biomarker for Early Predicting the Response of Subcutaneous Immunotherapy in Pediatric Allergic Rhinitis
Sijie Jiang,Shaobing Xie,Ruohao Fan,Qingping Tang,Hua Zhang,Fengjun Wang,Shumin Xie,Kelei Gao,Junyi Zhang,Zhihai Xie,Weihong Jiang
DOI: https://doi.org/10.2147/JIR.S379414
IF: 4.5
2022-09-03
Journal of Inflammation Research
Abstract:Sijie Jiang, 1– 3 Shaobing Xie, 1– 3 Ruohao Fan, 1– 3 Qingping Tang, 4 Hua Zhang, 1– 3 Fengjun Wang, 1– 3 Shumin Xie, 1– 3 Kelei Gao, 1– 3 Junyi Zhang, 1– 3 Zhihai Xie, 1– 3 Weihong Jiang 1– 3 1 Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha, People's Republic of China; 2 Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Xiangya Hospital of Central South University, Changsha, People's Republic of China; 3 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of Central South University, Changsha, People's Republic of China; 4 Department of Rehabilitation, Brain Hospital of Hunan Province, Hunan University of Chinese Medicine, Changsha, People's Republic of China Correspondence: Weihong Jiang, Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha, People's Republic of China, Tel +86-731-8975-3045, Email Purpose: Subcutaneous immunotherapy (SCIT) is an effective treatment for pediatric allergic rhinitis (AR), but its efficacy fluctuates among individuals. This study aims to identify the profile of serum exosomes derived microRNAs (miRNAs) and evaluate their capacities to early predict SCIT efficacy in pediatric AR. Patients and Methods: High-throughput sequencing was applied to identify the miRNA of serum exosomes in AR children. GO enrichment and KEGG pathway analysis were performed to enrich the biological annotations of target mRNAs of miRNAs. Then we validated differentially expressed miRNAs in two independent cohorts by RT-qPCR. Logistic regression and receiver operating characteristic curve (ROC) were applied to evaluate the abilities of identified miRNAs in predicting the efficacy of SCIT in AR children. Results: A total of 812 miRNAs were detected in the serum exosomes, including 16 upregulated and 14 downregulated. Differentially expressed genes are enriched in the biological process of developmental process and regulation of cellular process, and gathered in pathways such as the signaling pathways regulating pluripotency of stem cells and the Wnt signaling pathway. In the first validation cohort, hsa-miR-4669 (P=0.009) and hsa-miR-4686 (P=0.032) were significantly downregulated in the effective group than the ineffective group, while hsa-miR-3196 (P=0.015) was upregulated. In the second cohort, hsa-miR-4669 level (P< 0.0001) was downregulated in the effective group than the ineffective group. In addition, logistic regression revealed that hsa-miR-4669 level was correlated with the visual analogue scale (r=0.323, P=0.001) and total nasal symptoms score (r=0.269, P =0.007). ROC curve highlighted that hsa-miR-4669 level exhibited a reliable accuracy in predicting SCIT efficacy in pediatric AR (AUC=0.785). Conclusion: Serum exosomes derived miRNA were associated with the efficacy of SCIT. Serum exosomes derived hsa-miR-4669 might serve as a novel biomarker for early predicting the response of SCIT in AR children. Keywords: allergic rhinitis, subcutaneous immunotherapy, miRNA, exosome, children Allergic rhinitis (AR) is a common allergic disease caused by exposure to aeroallergens. 1,2 The prevalence rate of AR varies around the world and increased dramatically in recent years. According to longitudinal studies, AR mostly occurs in childhood, and the prevalence increases with the growth of age. 3,4 Several epidemiological questionnaires in China showed that the self-reported prevalence of AR in children ranged from 18.10% to 49.68%. 5–7 Meanwhile, a previous research reported that 42% of AR children accompanied with asthma. 8 AR has become a global public health problem with huge government sanitary investment, and it also brought heavy financial and mental burdens to patients. 2,9 Currently, AR therapies consist of allergen avoidance, antiallergic agents, allergen immunotherapy (AIT), and surgery. 1 Mainly performed subcutaneously (SCIT) or sublingually (SLIT), AIT is the only approach to alert the disease process and is generally recommended for allergic patients who respond poorly to pharmacotherapy. 10,11 SCIT exhibited better performance in symptom control and adherence, especially in children. 12–14 However, there still were some patients who did not respond well to SCIT, and AR children were at higher risk of adverse reactions during SCIT. 15–17 Therefore, a trustworthy biomarker to predict the clinical efficacy of SCIT was crucial. 18 Although previous publications discovered that IgG4 antibodies, serum periostin -Abstract Truncated-
immunology